Skip to main content
. 2021 Jun 20;8(16):2100250. doi: 10.1002/advs.202100250

Figure 2.

Figure 2

The small molecule FAK inhibitor IN10018 confers potent anti‐cancer effects against diverse KRAS mutant cell lines as well as CDX and PDX tumor models. A) Cell viability assay for the cell lines treated with IN10018. The cells except CO‐04‐0070 PDC were treated with different doses of IN10018 for 72 h. (Data represent mean ± SEM, n ≥ 3). B–L) In vivo evaluation of IN10018 effects on different cancer models taking KRAS mutation. The models were treated with vehicle control (0.5% Natrosol 250 HX) and 25 or 50 mg kg‐1 of IN10018. Body weights and tumor sizes of the mice were monitored twice a week. (Data represent mean ± SEM, n ≥ 5). Statistics analysis was done using unpaired student's T‐test. *P < 0.05, **P < 0.01, and ***P < 0.001. M–P) Western blot results for FAK signaling upon IN10018 treatment. The tumors from NCI‐H358, NCI‐H2122, SNU668, and mouse KPL models treated with IN10018 were taken for Western blot tests of FAK signaling.